Oxidative Medicine and Cellular Longevity · 2022 · 24 citations · 33 references
MedicineMolecular BiologyOncologyEpigeneticsGene ExpressionMolecular OncologyCancer Cell SignalingCancer EpigeneticsCancer TranscriptomicsEpigenetic Regulation In CancerMalignant NeoplasmsSignal Transduction In CancerCellular RadiosensitivityEpigenetic Responses To RadiationHepatocellular Carcinoma MetastasisHepatocellular Carcinoma PathogenesisHypoxia-inducible Factor RegulationHypoxia-inducible Factor SignalingMicrorna In CancerTumor Radiosensitivity
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase involved in cell proliferation, invasion, angiogenesis, and metastasis in various cancers, including hepatocellular carcinoma (HCC). However, the role and molecular mechanisms of EZH2 in HCC radiosensitivity remain unclear. Here, we show that EZH2 is upregulated in HCC cells and the aberrantly overexpressed EZH2 is associated with the poor prognosis of HCC patients. Using miRNA databases, we identified miR‐138‐5p as a regulator of EZH2. We also found that miR‐138‐5p was suppressed by EZH2‐induced H3K27me3 in HCC cell lines. MiR‐138‐5p overexpression and EZH2 knockdown enhanced cellular radiosensitivity while inhibiting cell migration, invasion, and epithelial‐mesenchymal transition (EMT). Analysis of RNA‐seq datasets revealed that the hypoxia‐inducible factor‐1 (HIF‐1) signaling pathway was the main enrichment pathway for differential genes after miR‐138‐5p overexpression or EZH2 knockdown. Expression level of HIF‐1 α was significantly suppressed after miR‐138‐5p overexpression or silencing of EZH2. HIF‐1 α silencing mitigated resistance of HCC cells and inhibited EMT. This study establishes the EZH2/miR‐138‐5p/HIF‐1 α as a potential therapeutic target for sensitizing HCC to radiotherapy.
33
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu, Zhenhua J. Wu, Anna C. Groner et al. · Science · 2012 · 879 citations · Full text